Peter Schneider于2025年9月30日离开AT&S管理委员会;CEO Michael Mertin担任临时领导。 Peter Schneider to leave AT&S Management Board Sept. 30, 2025; CEO Michael Mertin to lead interim.

AT&S宣布Peter Schneider将于2025年9月30日离开管理委员会, 首席执行官Michael Mertin担任临时领导; AT&S announced Peter Schneider will leave the Management Board on September 30, 2025, with CEO Michael Mertin taking interim leadership; the company gained 12.94% weekly. AMAG的下降率为0.41%。 AMAG declined 0.41%. 据Marinomed Biotech报道,该公司在2025年上半年表现强,销售额上升至720万欧元,EBIT从320万欧元的亏损上升至2100万欧元,受重组收益1930万欧元的推动;到6月30日,现金和现金等价物达到150万欧元,高于90万欧元. Marinomed Biotech reported strong first-half 2025 results, with sales rising to €7.2 million and EBIT turning to €21.0 million from a €3.2 million loss, driven by a €19.3 million restructuring gain; cash and cash equivalents reached €1.5 million by June 30, up from €0.9 million. 圣马力诺的股份下跌了3.73%。 Marinomed’s shares fell 3.73%. 从9月16日起任命Petra Preining为首席财务官, 公司股价上涨0. 25%。 Pierer Mobility appointed Petra Preining as CFO effective September 16, and the company’s stock rose 0.25%. 资本的增加将圣马力诺的股份资本提高到184万欧元。 A capital increase raised Marinomed’s share capital to €1.84 million. 市场活动包括Porr增加6.55%和ATX显示中性趋势。 Market activity included Porr gaining 6.55% and the ATX showing neutral trends. 欧盟委员会核准了Denosumab案,分析家们对2026年Flughafen Wien案持谨慎的看法。 The European Commission approved Denosumab, and analysts gave cautious outlooks for Flughafen Wien in 2026.